BMI Calculator
Calculate Body Mass Index for adults and children aged 2–20 years. Includes WHO/CDC classification, colour-coded risk categories, and paediatric percentile interpretation.
Calculate Adult BMI
Enter the patient’s weight and height to calculate Body Mass Index. Supports metric (kg/m) and imperial (lb/in) units. For patients aged 2–20 years, use the paediatric BMI calculator below, which provides age- and sex-specific percentile interpretation.
BMI is a screening tool that does not directly measure body fat. It does not account for muscle mass, bone density, age, sex, or fat distribution. Interpretation should always consider the full clinical picture, including waist circumference, body composition, and metabolic markers.
Calculate Paediatric BMI (Ages 2–20)
For children and adolescents aged 2–20 years, BMI is interpreted using age- and sex-specific percentiles from the CDC growth charts. Enter the child’s weight, height, age, and sex to calculate BMI and the corresponding percentile category.
In children, absolute BMI values cannot be compared directly to adult thresholds. A 10-year-old with a BMI of 22 kg/m² may be overweight, while the same BMI in an 18-year-old is within the healthy range. Always use age- and sex-specific percentiles for paediatric assessment.
Understanding Body Mass Index
Body Mass Index (BMI) is a simple anthropometric measure that uses a person’s weight and height to estimate whether they fall within a healthy weight range. First described by the Belgian statistician Adolphe Quetelet in the 1830s and later popularised by Ancel Keys in 1972, BMI remains one of the most widely used screening tools for categorising weight status at the population level.
BMI correlates with body fat percentage in most populations, though the relationship varies by age, sex, ethnicity, and body composition. At a population level, elevated BMI is associated with increased risk of type 2 diabetes, cardiovascular disease, certain cancers, and all-cause mortality.
Adult BMI Formula
Metric:
BMI = Weight (kg) ÷ Height² (m²)
Imperial:
BMI = [Weight (lb) ÷ Height² (in²)] × 703
Example: A 75 kg adult at 175 cm → BMI = 75 ÷ 1.75² = 75 ÷ 3.0625 = 24.5 kg/m² (Normal weight)
Paediatric BMI Percentile
For children aged 2–20, the same formula is used, but the result is plotted against age- and sex-specific CDC growth charts to obtain a percentile.
Example: A 10-year-old boy with BMI 18.5 kg/m² falls at approximately the 75th percentile — healthy weight. The same BMI in a 6-year-old boy would be above the 95th percentile — obesity.
Key distinction: BMI is a screening tool, not a direct measure of adiposity. It should prompt further evaluation (waist circumference, body composition, metabolic markers) rather than serve as a standalone diagnosis. Two patients with the same BMI can have markedly different body fat percentages and metabolic risk profiles.
BMI Categories & Interpretation
Adult Classification (WHO)
| BMI (kg/m²) | Category | Risk of Comorbidities | BMI Prime |
|---|---|---|---|
| <16.0 | Severe thinness | High (malnutrition, sarcopenia) | <0.64 |
| 16.0–16.9 | Moderate thinness | Moderate | 0.64–0.68 |
| 17.0–18.4 | Mild thinness | Low–moderate | 0.68–0.74 |
| 18.5–24.9 | Normal weight | Average | 0.74–1.00 |
| 25.0–29.9 | Overweight (Pre-obese) | Mildly increased | 1.00–1.20 |
| 30.0–34.9 | Obese — Class I | Moderate | 1.20–1.40 |
| 35.0–39.9 | Obese — Class II | Severe | 1.40–1.60 |
| ≥40.0 | Obese — Class III | Very severe | ≥1.60 |
Paediatric Classification (CDC, Ages 2–20)
| Percentile | Category | Clinical Implication |
|---|---|---|
| <5th | Underweight | Evaluate for nutritional deficiency, chronic illness, or eating disorder |
| 5th–84th | Healthy weight | Continue routine growth monitoring |
| 85th–94th | Overweight | Assess diet, activity, family history; monitor trend over time |
| ≥95th | Obesity | Comprehensive evaluation; consider metabolic screening |
| ≥120% of 95th | Severe obesity | Higher comorbidity risk; multidisciplinary referral recommended |
The most common interpretation error is applying adult BMI cut-offs to children. A child with BMI 27 may appear “normal” by adult standards but could be well above the 95th percentile for their age and sex. Paediatric BMI must always be interpreted as a percentile using age- and sex-specific growth charts.
Clinical Considerations & Health Risks
BMI is associated with a wide spectrum of health outcomes. The relationship between BMI and morbidity is not linear — both very low and very high BMI carry increased risk. The following sections outline the major clinical domains affected by weight status.
Elevated BMI is one of the strongest modifiable risk factors for cardiovascular disease. Excess adiposity — particularly visceral fat — promotes a pro-inflammatory state, insulin resistance, dyslipidaemia, and hypertension, all of which accelerate atherosclerosis.
- Hypertension: Risk increases progressively from BMI ≥25. Each 5 kg/m² increase is associated with approximately 5 mmHg higher systolic blood pressure.
- Dyslipidaemia: Obesity raises LDL and triglycerides while lowering HDL. The metabolic pattern is typically driven by insulin resistance and hepatic lipid overproduction.
- Coronary artery disease: Overweight and obesity increase CAD risk independently, though much of the effect is mediated through hypertension, diabetes, and lipid abnormalities.
- Heart failure: Obesity is a risk factor for both HFpEF and HFrEF, with a paradoxical survival benefit observed in some established heart failure populations (the “obesity paradox”).
Adipose tissue is an active endocrine organ. Excess adiposity disrupts glucose homeostasis, promotes chronic low-grade inflammation, and alters sex hormone metabolism. Key metabolic consequences include:
- Type 2 diabetes: The risk of T2DM rises steeply with BMI. Overweight individuals face 2–3× the risk, while those with BMI ≥35 face 5–10× the risk compared to normal weight.
- Metabolic syndrome: Defined by the clustering of abdominal obesity, dyslipidaemia, hypertension, and impaired fasting glucose. Central obesity (waist circumference) is often more predictive than BMI alone.
- Non-alcoholic fatty liver disease (NAFLD): Affects up to 80% of individuals with obesity. Progression to steatohepatitis and cirrhosis is a growing cause of liver disease worldwide.
- Polycystic ovary syndrome (PCOS): Obesity worsens insulin resistance, androgen excess, and anovulation in PCOS. Weight reduction of 5–10% often improves symptoms significantly.
The International Agency for Research on Cancer (IARC) identifies excess body fatness as a risk factor for at least 13 cancer types. Proposed mechanisms include chronic hyperinsulinaemia, increased bioavailable sex hormones, and inflammation-driven cellular proliferation.
- Strong associations (RR >1.5): Endometrial, oesophageal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma
- Moderate associations (RR 1.1–1.5): Postmenopausal breast cancer, colorectal, pancreatic, gallbladder, ovarian, thyroid
- Emerging evidence: Multiple myeloma, meningioma, gastric cardia
The population-attributable fraction of obesity-related cancers is substantial and increasing. Weight management may be an under-utilised cancer prevention strategy.
Excess weight places mechanical stress on joints and restricts respiratory mechanics. Common musculoskeletal and respiratory complications include:
- Osteoarthritis: Weight-bearing joints (knees, hips) are disproportionately affected. Each 5 kg/m² increase in BMI roughly doubles knee OA risk. Weight loss reduces symptoms and may slow disease progression.
- Low back pain: Both mechanical loading and systemic inflammation contribute to increased rates of lumbar disc disease and chronic pain in obesity.
- Obstructive sleep apnoea: Strongly associated with BMI ≥30. Central adiposity narrows the pharyngeal airway. Prevalence in severe obesity exceeds 50%.
- Obesity hypoventilation syndrome: A more severe form of respiratory compromise with chronic hypercapnia, seen in BMI ≥40 and often under-recognised.
A BMI below 18.5 is associated with its own set of health risks, which are often under-appreciated in clinical practice. Low BMI may indicate undernutrition, sarcopenia, or an underlying chronic disease.
- Increased mortality: Studies consistently show a J- or U-shaped mortality curve, with elevated risk at both extremes of BMI. Underweight adults have higher all-cause mortality compared to those in the normal range.
- Immune dysfunction: Malnutrition impairs both humoral and cell-mediated immunity, increasing susceptibility to infection and impairing wound healing.
- Osteoporosis: Low BMI is an independent risk factor for reduced bone mineral density and fragility fractures, particularly in postmenopausal women and elderly men.
- Sarcopenia: Loss of muscle mass accompanies low BMI and is associated with functional decline, falls, and increased post-surgical morbidity.
When a patient’s BMI falls outside the healthy range, the next step is to contextualise the result. Measure waist circumference (central adiposity marker), assess for metabolic syndrome components (fasting glucose, lipid profile, blood pressure), and explore lifestyle factors including diet, physical activity, sleep, and psychosocial stressors before formulating a management plan.
Special Populations & Adjusted Thresholds
Standard BMI thresholds were derived primarily from European-descent populations. Body composition varies by ethnicity, age, and physiological state, requiring adjusted interpretation in certain groups.
Take-home point: BMI thresholds are population-derived screening tools. In individual patients — especially those who are elderly, very muscular, from non-European backgrounds, or pregnant — the clinical significance of a given BMI value may differ substantially from the standard WHO classification.
Systematic Clinical Approach to Abnormal BMI
A structured approach helps clinicians move beyond BMI as a number and toward a comprehensive weight-status assessment. The following framework is adapted from major obesity guidelines.
Measure height and weight accurately — remove shoes, light clothing. Calculate BMI and compare to prior measurements to establish the trajectory. In children, plot on the appropriate growth chart to determine the percentile trend over time, not just a single data point.
Consider factors that may affect interpretation: fluid overload (e.g., heart failure, renal disease), amputations (adjust with correction factors), pregnancy (use pre-pregnancy BMI), and muscular build. Contextualising the BMI prevents reflex over- or under-diagnosis.
Measure waist circumference at the midpoint between the lowest rib and iliac crest. Central obesity (men ≥94 cm, women ≥80 cm by IDF criteria; or ≥102 cm / ≥88 cm by ATPIII) carries greater cardiometabolic risk than peripheral adiposity, independent of BMI.
Waist-to-height ratio (>0.5 indicating elevated risk) is a simpler alternative that adjusts for body size and performs well across age groups and ethnicities. In research or specialist settings, DEXA or bioelectrical impedance may quantify body composition more precisely.
For patients with BMI ≥25 (or ≥23 in Asian populations), screen for metabolic syndrome components and obesity-related conditions:
- Fasting glucose or HbA1c (prediabetes / type 2 diabetes)
- Fasting lipid profile (dyslipidaemia)
- Blood pressure (hypertension)
- Liver function tests + hepatic steatosis assessment (NAFLD)
- Thyroid function (hypothyroidism as a contributing factor)
- Uric acid (gout risk)
This metabolic screening stratifies patients into “metabolically healthy” versus “metabolically unhealthy” phenotypes, which helps guide the intensity of intervention independent of BMI class.
Management intensity should match risk. Not every overweight patient requires aggressive intervention, and not every patient with normal BMI is risk-free.
- BMI 25–29.9, no complications: Lifestyle counselling (diet, physical activity, behavioural change). Prevent further weight gain.
- BMI 25–29.9 with complications OR BMI 30–34.9: Structured lifestyle intervention. Consider pharmacotherapy if lifestyle change is insufficient after 3–6 months.
- BMI 35–39.9 with complications OR BMI ≥40: Intensive lifestyle + pharmacotherapy. Evaluate for metabolic/bariatric surgery if conservative measures fail.
- BMI <18.5: Evaluate for underlying cause (malignancy, malabsorption, eating disorder, chronic illness). Nutritional rehabilitation and monitoring.
Common Pitfalls & Limitations
BMI is a proxy for body fatness, not a direct health metric. It does not distinguish between fat mass and lean mass, does not assess fat distribution, and cannot identify “metabolically healthy obesity” or “normal-weight metabolic disease.” A patient with a BMI of 24 who is physically inactive, sarcopenic, and has metabolic syndrome is at higher risk than a fit patient with a BMI of 28 and normal metabolic parameters. BMI should be the starting point for assessment, not the endpoint.
Applying adult BMI categories to children is one of the most common errors. Because body composition changes with age and differs between sexes during growth, a fixed BMI number has no clinical meaning without age and sex context. A BMI of 20 is overweight in a 4-year-old but perfectly normal in a 16-year-old. Always use CDC or WHO growth charts and interpret BMI as a percentile in patients aged 2–20 years.
Standard WHO thresholds were developed from predominantly European cohorts. South Asian, East Asian, and Southeast Asian populations develop metabolic complications at lower BMI values because of differences in body fat distribution and percentage. Applying a universal cut-off of 25 for overweight may miss at-risk patients in these groups. The WHO Expert Consultation (2004) recommends using 23 as the overweight threshold and 27.5 as the obesity threshold for Asian populations.
Clinical attention disproportionately focuses on overweight and obesity, but underweight carries significant morbidity and mortality. Low BMI may signal eating disorders, malignancy, malabsorption, chronic infection, or depression. In elderly patients, unintentional weight loss and low BMI are strong independent predictors of mortality and functional decline. A thorough evaluation of the underweight patient — including nutritional assessment, cancer screening, and mental health evaluation — is clinically important.
In paediatric practice, a single BMI percentile provides a snapshot, but the trajectory over time is far more informative. A child whose BMI percentile is crossing upward (e.g., from the 60th to the 90th over 12 months) may warrant earlier intervention than a child who has been stable at the 88th percentile for years. Growth charts should be reviewed longitudinally at every well-child visit, and sharp changes in trajectory should prompt evaluation for contributory factors.
Quick Reference Summary
| Scenario | Key Action |
|---|---|
| BMI 18.5–24.9 (adult) | Reassure; routine monitoring |
| BMI 25–29.9, no complications | Lifestyle counselling; prevent further gain |
| BMI ≥30 or 25–29.9 with complications | Structured lifestyle ± pharmacotherapy |
| BMI ≥40 or ≥35 with complications | Consider metabolic/bariatric surgery referral |
| BMI <18.5 (adult) | Evaluate for underlying cause; nutritional support |
| Paediatric ≥85th–94th percentile | Assess diet/activity; monitor trend |
| Paediatric ≥95th percentile | Comprehensive evaluation; metabolic screening |
The Golden Rule: BMI opens the conversation — it does not close it. Every abnormal BMI should trigger a clinical assessment of body composition, metabolic parameters, and contributory factors before a management plan is formed.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. 1972;25(6-7):329-343. DOI: 10.1016/0021-9681(72)90027-6
- World Health Organization. Obesity: preventing and managing the global epidemic. WHO Technical Report Series 894. Geneva: WHO; 2000. Available at: WHO TRS 894
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. DOI: 10.1016/S0140-6736(03)15268-3
- Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11. 2002;(246):1-190. Available at: CDC Growth Charts
- Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120 Suppl 4:S164-S192. DOI: 10.1542/peds.2007-2329C
- Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71-82. DOI: 10.1001/jama.2012.113905
- Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014;129(25 Suppl 2):S102-S138. DOI: 10.1161/01.cir.0000437739.71477.ee
- Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity — assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709-757. DOI: 10.1210/jc.2016-2573
- Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798. DOI: 10.1056/NEJMsr1606602
- Institute of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: National Academies Press; 2009. DOI: 10.17226/12584